Heart disease and stroke statistics2019 update: a report from the American Heart Association
Watch the video below to see my very first B12 injection
About 40-50,000 patients receive GLP-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors(SGLT-2i) drugs, 84,000 were treated with dipeptidyl peptidase-4 (DPP-4) and more than 200,000 received sulfonylureas, with tracking of major adverse outcomes of all-cause mortality, heart attack, stroke, need for coronary revascularization
Activation of the glucagon receptor increases energy expenditure and may help reduce liver fat
We offer seminars, workshops, support groups, and counseling on life after treatment